What's new? Log in Free sign up

Qiagen (QGEN)

Company Profile

Company profile

Ticker

QGEN

Exchange

Website

CEO

Mr. Thierry Bernard

Incorporated

Location

Fiscal year end

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • American National • Gilead Sciences • Biogen • Moderna • Bio-Techne • Acorda Therapeutics • BioNTech SE • Gladstone Investment ...

Former names

[object Object]

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

QGEN stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

QIAGEN announces 2028 strategy for solid profitable growth

Current report (foreign)

Conflict minerals disclosure

Registration of securities for employees

Current report (foreign)

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

WELLINGTON MANAGEMENT GROUP LLP

BlackRock, Inc.

BlackRock, Inc.

Notice of proposed sale of securities

MASSACHUSETTS FINANCIAL SERVICES CO /MA/

MASSACHUSETTS FINANCIAL SERVICES CO /MA/

Notice of proposed sale of securities

MASSACHUSETTS FINANCIAL SERVICES CO /MA/

Financial summary

Financial statements Chart QGEN financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Qiagen earnings reports.

Institutional ownership, Q2 2024

QGEN institutional ownership history Ownership history

66.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	299	238	+25.6%
Opened positions	98	190	-48.4%
Closed positions	37	18	+105.6%
Increased positions	93	21	+342.9%
Reduced positions	76	27	+181.5%

13F shares	Current	Prev Q	Change
Total value	5.82 tn	4.51 tn	+29.0%
Total shares	150.44 mm	114.22 mm	+31.7%
Total puts	500.81 k	193.60 k	+158.7%
Total calls	1.06 mm	1.04 mm	+1.0%
Total put/call ratio	0.5	0.2	+156.1%

Largest owners	Shares	Value	Change
Massachusetts Financial Services	23.20 mm	$953.14 bn	-0.2%
Wellington Management	11.96 mm	$493.43 bn	+25.8%
Vanguard	8.85 mm	$363.79 bn	+2.2%
BLK BlackRock	7.63 mm	$313.42 bn	-0.2%
Capital International Investors	7.46 mm	$306.45 bn	NEW
Amundi	5.94 mm	$240.95 bn	-14.0%
Nuance Investments	5.27 mm	$216.61 bn	+17.3%
Norges Bank	4.19 mm	$172.99 bn	NEW
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main	4.04 mm	$167.00 bn	+15.7%
Earnest Partners	3.81 mm	$156.44 bn	NEW

Largest transactions	Shares	Bought/sold	Change
Capital International Investors	7.46 mm	+7.46 mm	NEW
Norges Bank	4.19 mm	+4.19 mm	NEW
Earnest Partners	3.81 mm	+3.81 mm	NEW
BAC Bank of America	3.43 mm	+3.43 mm	NEW
Millennium Management	3.03 mm	+3.03 mm	NEW
Wellington Management	11.96 mm	+2.45 mm	+25.8%
FIL	1.34 mm	-2.36 mm	-63.7%
Citadel Advisors	2.14 mm	+2.14 mm	NEW
Southpoint Capital Advisors	2.00 mm	+2.00 mm	NEW
LGEN Legal & General	2.18 mm	+1.88 mm	+637.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

QIAGEN Launches AI-Extension Of Ingenuity Pathway Analysis For Automatic Interpretation Of Biological Data

Ingenuity Pathway Analysis Interpret extends analysis capabilities of human-curated knowledge base with AI technologyAI-extension highlights key biological elements at work and provides summarized results and

Jefferies Assumes Qiagen at Buy, Raises Price Target to $54

Jefferies analyst Tycho Peterson assumes Qiagen (NYSE:QGEN) with a Buy rating and raises Price Target to $54.

QIAGEN Achieves Milestone With Over 1,000 Placements Of EZ2 Connect Sample Preparation Instrument

EZ2 Connect for automated nucleic acid purification has reached over 1,000 placements worldwide, contributing to a global installed base of more than 5,500 EZ series instrumentsComprehensive portfolio of EZ2 Connect

Reported Thursday, QIAGEN Boosts QIAstat-Dx With New Barcelona Hub For Infectious Disease And Precision Medicine Testing

Syros Pharmaceuticals Gave Notice To Qiagen Manchester Limited Of Its Election To Terminate The Master Collaboration Agreement Dated March 7, 2022

Press releases

From Benzinga Pro

QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data

Ingenuity Pathway Analysis Interpret extends analysis capabilities of human-curated knowledge base with AI technology AI-extension highlights key biological elements at work and provides summarized results and

QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation

EZ2 Connect for automated nucleic acid purification has reached over 1,000 placements worldwide, contributing to a global installed base of more than 5,500 EZ series instruments Comprehensive portfolio of EZ2

QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis

Venlo, the Netherlands, Nov. 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the launch of two new tools for designing and ordering custom solutions that can be used to

QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics

QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.